Overall, this work is important to understand the mechanism for clinical candidates targeting GIPR for the treatment of obesity, either agonists or antagonists, that chronically both inhibit the activity of GIPR at least in adipose tissue and potentially in others, such as adrenal glands or the brain. Here, GIPR is linked to obesity due to melanocortin 4 receptor deficiency.